^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PGR positive

i
Entrez ID:
Related biomarkers:
2d
Insulin-like growth factor binding protein-6 modulates proliferative antagonism in response to progesterone in breast cancer. (PubMed, Front Endocrinol (Lausanne))
Stable overexpression of IGFBP-6 in MCF-7 cells resulted in an increase in Epidermal Growth Factor Receptor (EGFR) and this expression was further enhanced when cells were cotreated with progesterone and estradiol. These results indicate that IGFBP-6 is a regulator of progesterone action, and that PR is required for the observed protective effects of IGFBP-6 in breast cancer.
Journal
|
EGFR (Epidermal growth factor receptor) • PGR (Progesterone receptor) • CCNE2 (Cyclin E2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IGFBP6 (Insulin Like Growth Factor Binding Protein 6)
|
HR positive • EGFR expression • PGR positive
2d
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (clinicaltrials.gov)
P3, N=701, Recruiting, Celcuity Inc | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
|
ER positive • PIK3CA mutation • PGR positive
|
Ibrance (palbociclib) • Piqray (alpelisib) • fulvestrant • gedatolisib (PF-05212384)
4d
Enrollment closed • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • PGR positive
|
paclitaxel • ImmuFact (eftilagimod alpha)
6d
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial. (PubMed, J Natl Cancer Inst)
Our study suggests differential tamoxifen benefit by menopausal status. Improved long-term endocrine therapy prediction in premenopausal patients is needed and could involve molecular markers because standard tumor characteristics cannot predict benefit beyond 10 years.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
tamoxifen
8d
RaPhLRR: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (clinicaltrials.gov)
P2, N=200, Recruiting, Oana Danciu | Trial completion date: Dec 2027 --> Aug 2029 | Trial primary completion date: Dec 2024 --> Aug 2028
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
9d
Association between long-term ambient air pollution exposure and the incidence of breast cancer: A meta-analysis based on updated evidence. (PubMed, Ecotoxicol Environ Saf)
This study is the first to document a significant association between long-term exposure to ambient PM2.5 and breast cancer incidence through meta-analysis. Air pollution has a pronounced impact on postmenopausal breast cancer, and the strength of the association between specific air pollutants and breast cancer incidence varies across regions. These findings suggest that long-term exposure to NO2 and PM2.5 may increase the incidence of breast cancer.
Retrospective data • Review • Journal
|
PGR (Progesterone receptor)
|
ER positive + PGR positive • PGR positive • PGR negative
11d
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Phase classification: P1/2 --> P1 | Trial completion date: Mar 2025 --> Jul 2025
Phase classification • Trial completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
|
HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + PGR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)
12d
Enrollment closed • Metastases
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • PGR positive • BRCA mutation
|
Lynparza (olaparib)
29d
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Apr 2017 --> Sep 2024
Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive • HER-2 negative + PGR positive
|
carboplatin • veliparib (ABT-888)
30d
Early Breast Cancer Treated with Adjuvant S-1 plus Endocrine Therapy-A Report of Two Cases (PubMed, Gan To Kagaku Ryoho)
We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
Teysuno (gimeracil/oteracil/tegafur)
30d
Long-Term Response to CDK4/6 Inhibitor for Multiple Metastases of Breast Cancer (PubMed, Gan To Kagaku Ryoho)
Surgery was not possible due to comorbidities, so fulvestrant(500 mg/month)+denosumab(120 mg/month)was started. Furthermore, as the tumor markers were elevated, abemaciclib(300 mg/day)was added, which resulted in a decrease in the tumor markers...During the course of treatment, the tumor markers rose again, so the dose was increased to 250 mg/day, which resulted in a decrease in the tumor markers and good tolerability. At present, 36 months after the start of treatment, long SD has continued, no adverse events of grade 3 or higher have been observed, and the drug has been well tolerated.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
Verzenio (abemaciclib) • fulvestrant • Prolia (denosumab)
1m
Dormancy Leading to Late Recurrence in Breast Cancer: A Case of Hormone Receptor-Positive Supraclavicular Metastasis 10 Years After the Initial Treatment. (PubMed, Cureus)
Her treatment was adjusted to include Faslodex (fulvestrant) and Verzenio (abemaciclib), followed by the surgical resection of the metastatic lymph node. Understanding dormancy and reactivation mechanisms is essential for guiding clinical decisions. Prioritizing individualized follow-up strategies and refining treatment protocols will be key to improving patient outcomes and maintaining quality of life.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive • EGFR positive
|
Verzenio (abemaciclib) • fulvestrant
1m
Immunohistochemical-Based Molecular Subtypes of Female Breast Cancer: A Retrospective Cross-Sectional Study at Cheikh Khalifa Hospital in Casablanca, Morocco. (PubMed, Cancer Control)
Our findings should be used to guide breast cancer management policies in Morocco. Larger cohort studies are needed to determine the specificity of the breast cancer profile in Morocco as well as the epidemiological risk factors specific to every subtype.
Observational data • Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HR positive • PGR positive
1m
Financial Difficulty Over Time in Young Adults With Breast Cancer. (PubMed, JAMA Netw Open)
In this cohort study of young adults with breast cancer, we identified a subset of patients who experienced a high degree of financial difficulty persisting into early survivorship. Targeted interventions to mitigate financial toxicity-modifiable factors that include support for the employability or return to work support for those experiencing arm symptoms after treatment-are needed.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive • PGR positive
1m
ADAPTcycle: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (clinicaltrials.gov)
P3, N=1684, Active, not recruiting, West German Study Group | Recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
Kisqali (ribociclib)
1m
Current status and influencing factors of patients in endocrine therapy for breast cancer (ChiCTR2400089127)
P=N/A, N=288, Recruiting, The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University
New trial
|
PGR (Progesterone receptor)
|
PGR positive
1m
Neoadjuvant endocrine therapy for breast cancer (ChiCTR2400088944)
P2, N=60, Recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • HER-2 expression • PGR positive • PTEN mutation + HR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
1m
APBI Proton Feasibility and Phase II Study (clinicaltrials.gov)
P1/2, N=40, Completed, Abramson Cancer Center at Penn Medicine | Phase classification: P=N/A --> P1/2
Phase classification
|
PGR (Progesterone receptor)
|
PGR positive
2ms
HELEN-008: Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer (clinicaltrials.gov)
P3, N=1979, Recruiting, Henan Cancer Hospital | Trial primary completion date: Sep 2024 --> Sep 2025
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR positive • HER-2 negative + PGR positive
|
capecitabine
2ms
Prognostic Value of high-risk Oncotype Recurrence Score (RS) and MammaPrint (MP) assay in Premenopausal African American (AA) Patients with Hormone-Positive (HR+), Node-Negative Breast Cancer (BC): A Study of the National Cancer Database (NCDB). (SABCS 2024)
Our study shows that among high genomic risk, node-negative, premenopausal patients, the survival rates are numerically similar between Caucasians and African Americans (AAs) when chemotherapy was administered. However, when chemotherapy was omitted, there were numerical differences in the survival rates within the high-risk RS population. This trend was not observed with the MP cohort.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR positive • HER-2 negative + PGR positive
|
MammaPrint • Oncotype DX Breast Recurrence Score®Test
2ms
Metastatic disease in patients with early breast cancer and a low Oncotype DX® Recurrence Score: A review of clinicopathological features (SABCS 2024)
57.14% (4/7) received adjuvant Letrozole for a minimum of 5 years. The patient with a recurrence score of 24 received adjuvant chemotherapy and developed metastatic 4 years post diagnosis while on Tamoxifen...Genomic tests have resulted in a significant reduction in the number of patients receiving adjuvant chemotherapy. However, a more multifacted approach may be required to tailor treatment decisions incorporating genomic testing, clinicopathological features and individual characteristics with the aim of improving outcomes for patients with hormone receptor positive early breast cancer.
Clinical • Review • Metastases
|
PGR (Progesterone receptor)
|
HR positive • PGR positive
|
Oncotype DX Breast Recurrence Score®Test
|
tamoxifen • letrozole
2ms
Effectiveness of Predictive Calculators for Breast Cancer Recurrence: A Comparative Study with the 21-Gene Score (SABCS 2024)
Only the established Johns Hopkins University calculator demonstrated good performance in correctly stratifying our patients. This highlights the need for further refinement and validation in predictive models across diverse patient populations to optimize medical decisions.
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • PGR positive • PGR negative • HER-2 negative + PGR positive
|
Oncotype DX Breast Recurrence Score®Test
2ms
The 70-Gene Signature Assay vs. Traditional Clinical Risk Assessment: Impact on Adjuvant Chemotherapy Choices in Mexican Breast Cancer Patients (SABCS 2024)
The NPI value is calculated based on tumor size, number of lymph nodes and tumor grade (11), The PREDICT program algorithm was developed from data of the East Anglia Cancer Registry and Information Centre (ECRIC) on patients with primary breast cancer treated in 1999-2003 and provides 5- and 10-year survival estimates with and without adjuvant systemic therapy (hormonal therapy, chemotherapy and trastuzumab) (13)...Although limited by sample size and lack of follow-up, these findings emphasize the value of integrating genomic tools with conventional methods to enhance personalized treatment. Future large-scale studies with follow-up are needed to confirm these results and fully establish the clinical utility of the 70-Gene Signature Assay in Mexican patients.
Clinical • Gene Signature
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • ER negative • PGR positive
|
MammaPrint
|
Herceptin (trastuzumab)
2ms
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer (clinicaltrials.gov)
P1, N=54, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Phase classification: P1/2 --> P1 | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
Phase classification • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • PGR positive
|
Lynparza (olaparib) • Ibrance (palbociclib) • fulvestrant
2ms
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
2ms
Utility of 18F-fluoroestradiol over 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the initial diagnosis of over 90 metastatic lesions in a patient with metastatic estrogen receptor-positive breast cancer. (PubMed, Proc (Bayl Univ Med Cent))
Due to discordant imaging findings, the patient then underwent 18F-FES PET/CT, which demonstrated over 90 metastatic osseous lesions. This study highlights the utility of 18F-FES PET/CT over 18F-FDG PET/CT in diagnosis of metastatic osseous lesions in a patient with metastatic estrogen receptor-positive breast cancer.
Journal • FDG PET • Metastases
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • ER positive + PGR positive • PGR positive
2ms
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer (SWOG-Fall 2024)
Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic, or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy. No participants are currently ineligible. There have been no Grade 4 or higher adverse events reported among the 26 participants assessed for adverse events.
Clinical • P3 data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive • EGFR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
MammaPrint
|
Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride
2ms
Trial completion • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
2ms
TBCRC 048: Olaparib in Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=114, Active, not recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
Trial completion date • Trial primary completion date • Metastases
|
PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCF (FA complementation group F) • FANCM (FA Complementation Group M) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)
|
BRCA2 mutation • BRCA1 mutation • HR positive • PALB2 mutation • PGR positive • BRCA mutation
|
Lynparza (olaparib)
2ms
Invasive Ductal Carcinoma of the Breast Presenting With Contralateral Axillary Lymph Node Metastasis: A Case Report. (PubMed, Cureus)
This patient had a history of right ER/PR positive HER2 negative stage 1 breast cancer s/p lumpectomy with sentinel lymph node biopsy and radiation plus tamoxifen x6 months in 2017...No right-sided sentinel node was identified. The right breast lesions and the left axillary lymph node metastases are all morphologically similar and showed strong ER expression, the results of which are compatible with spreading to the contralateral axilla.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
tamoxifen
2ms
Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. (PubMed, Lancet)
Most of the improvement in trial outcomes is explained by a greater proportion of women with lower-risk disease entering trials and improved adjuvant treatment. After adjustment, women diagnosed since 2000 have about a fifth lower rate of distant recurrence than the 1990s. Long-term risks of distant recurrence for oestrogen receptor-positive disease remain, but are about a tenth lower now than in our previous report.
Retrospective data • Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative • PGR positive
2ms
Molecular subtypes and clinicopathologic characteristics of cancers included in the Malmö Breast ImaginG database (EUSOBI 2024)
In the next phase, we aim to combine transcriptomic information with radiographic features to develop image-based breast cancer risk prediction models. This can aid in individualized breast cancer risk assessment and potentially guide personalized screening, prevention recommendations, and treatment decisions.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + PGR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
2ms
NORDIS: Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (clinicaltrials.gov)
P=N/A, N=50, Recruiting, Stanford University | Trial primary completion date: Sep 2024 --> Dec 2024
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • PGR positive
2ms
Single-cell multiplex immunocytochemistry in cell block preparations of metastatic breast cancer confirms sensitivity of GATA-binding protein 3 over gross cystic disease fluid protein 15 and mammaglobin. (PubMed, Cancer Cytopathol)
For a single marker, GATA3 displayed the highest sensitivity. The addition of MMG for hormone receptor-positive breast cancers and GCDFP15 for hormone receptor-negative breast cancers further increased sensitivity. The low proportion of multimarker-positive cells suggested that the coexpression observed with traditional ICC is attributable to intratumoral heterogeneity, not genuine coexpression.
Journal • Cell block • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • GATA3 (GATA binding protein 3)
|
ER positive • HR positive • HER-2 overexpression • HR negative • PGR positive • EGFR positive • HER-2 overexpression + HR negative • HER-2 overexpression + HR positive
3ms
Immunoglobulin A-dominant membranoproliferative glomerulonephritis-like pattern of injury as a possible paraneoplastic nephropathy in a breast cancer patient. (PubMed, CEN Case Rep)
IgA nephropathy with glomerular capillary IgA deposition is known to be resistant to corticosteroid therapy. The favorable clinical course of the rare glomerulopathy following breast cancer treatment suggested a diagnosis of paraneoplastic glomerulopathy secondary to breast cancer in our patient.
Journal
|
PGR (Progesterone receptor)
|
ER positive + PGR positive • PGR positive
3ms
Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • HMGB1 (High Mobility Group Box 1)
|
HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
3ms
Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
Avastin (bevacizumab) • sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • SHR-A2102 • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
3ms
CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov)
P1/2, N=255, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • PGR positive
|
Piqray (alpelisib) • Kisqali (ribociclib) • letrozole
3ms
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
3ms
Invasive lobular carcinoma of the male breast: A case report. (PubMed, Radiol Case Rep)
Treatment typically follows protocols for female breast cancer, including surgery, chemotherapy, and hormone therapy, with tamoxifen being commonly used. Further research is needed to better understand its pathogenesis and to develop more effective, tailored treatments.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
|
tamoxifen
3ms
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=170, Active, not recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
|
gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
3ms
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors (clinicaltrials.gov)
P1/2, N=3, Completed, Valerio Therapeutics | Recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | N=115 --> 3 | Trial completion date: Apr 2027 --> Oct 2023 | Trial primary completion date: Dec 2026 --> Oct 2023
Trial completion • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Pan tumor
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • PGR positive
|
Lynparza (olaparib) • AsiDNA (etidaligide)